A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This open-label randomized 2 arm study will determine the emergence of viral resistance in
participants with seasonal influenza A infection treated with oseltamivir. Eligible
participants less than or equal to (=) 5 years of age will be randomized to receive
oseltamivir at either standard dose (30-75 milligrams [mg] orally twice daily [bid]) or
double dose (60-150 mg orally bid) for 5 days. Target sample size is greater than (>) 100.